Full-Time

Principal Scientist

Vector Biology

Updated on 5/26/2026

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

No salary listed

Philadelphia, PA, USA

In Person

Category
Biology & Biotech
Requirements
  • MS degree with 10+ years; or PhD degree with ~5-8+ years of progressive industry experience in Bioengineering, Cell Biology and Chemical Engineering, or a closely related discipline. Advanced degree (PhD) with a molecular biology or virology foundation is preferred for this Principal Scientist role in early process development.
  • Demonstrated hands-on expertise in viral vector production, upstream process development, and characterization across multiple development scales, with a clear track record of translating early research-stage processes toward manufacturable, scalable platforms (required).
  • Substantial experience in mammalian suspension cell culture and upstream bioprocessing, with meaningful exposure to molecular biology workflows relevant to viral vector construct engineering.
  • Experience with bioreactor operations (up to 50 L preferred) and familiarity with downstream processing operations including clarification, chromatographic purification, and tangential flow filtration with the ability to apply downstream process constraints to upstream design decisions is a strong differentiator.
  • Meaningful early process development experience within gene therapy or viral vector platforms, with direct hands-on contribution to defining manufacturable upstream processes from concept through bioreactor scale.
  • Exceptional analytical acumen and structured scientific reasoning; experienced in the application of Design of Experiments (DoE), multivariate data analysis, and risk-based decision frameworks to accelerate early process development and maximize learning efficiency.
  • Demonstrated commitment to scientific rigor and research data integrity, with proficiency in maintaining meticulous, contemporaneous electronic laboratory notebook records that ensure experimental reproducibility and are structured to support future GxP-aligned technology transfer activities.
  • Highly organized and execution-oriented, with demonstrated capacity to manage multiple concurrent early development workstreams, prioritize effectively in a fast-paced R&D environment, and deliver scientifically sound results within program-driven timelines.
  • Exemplary oral and written communication skills, with the ability to translate complex early process development findings into compelling scientific narratives for diverse audiences including R&D leadership, CMC colleagues, and cross-functional program teams while operating with equal effectiveness as a self-directed scientific contributor and an engaged collaborative partner
  • Proficiency in molecular biology techniques central to viral vector construct design, including plasmid architecture and engineering, packaging system configuration, promoter selection and regulatory element optimization, transgene design, and transfer vector development to support LVV platform optimization (preferred).
  • Working knowledge of downstream processing operations —encompassing harvest and clarification strategies, affinity and ion-exchange chromatography, and tangential flow filtration — with the scientific acuity to incorporate purification process requirements and vector quality attribute targets into upstream process design; experience in integrated upstream-downstream process development is preferred.
Responsibilities
  • Establish and optimize early-stage seed train strategies from shake flask through bench-scale bioreactor, defining the foundational process parameters, cell culture conditions, and operational ranges that will underpin a scalable and manufacturable LVV platform.
  • Apply molecular biology expertise to evaluate LVV constructs encompassing plasmid architecture, packaging system selection, promoter and transgene configuration, and transfer vector optimization to establish high-performing, platform-compatible vectors that meet manufacturability and potency requirements for in-vivo CAR-T applications.
  • Design and optimize LVV production workflows, including transient transfection systems and emerging stable producer cell line platforms, to systematically improve vector yield, product quality attributes, and process robustness as part of an integrated early process development strategy.
  • Conduct systematic media optimization, feeding strategy evaluation, and bioreactor process control development to define process setpoints, identify critical process parameters, and establish the mechanistic understanding needed to support scale-up to 40-L and beyond.
  • Partner closely with Downstream colleagues to understand purification process constraints and integrate upstream design decisions including harvest conditions, clarification approaches, and vector quality attributes that enable a cohesive, end-to-end manufacturable process.
  • Design and execute fit-for-purpose early process development studies to generate the foundational data packages required for process lock, comparability assessments, and downstream regulatory filings; apply structured Design of Experiments and risk-based approaches to maximize information yield.
  • Serve as the upstream scientific lead within Vector Biology, providing authoritative technical input to cross-functional forums on construct-process relationships, early development strategy, and the stage-appropriate advancement of research findings into formal process development programs aligned with IND-enabling timelines.
  • Exercise a high degree of scientific independence in designing and executing complex experiments; proactively identify technical risks, generate mechanistic hypotheses, and implement data-driven solutions with minimal oversight to keep early development programs on track.
  • Synthesize complex experimental datasets into clear, structured data packages and deliver evidence-based technical recommendations that drive go/no-go decisions, inform process development strategy, and support program progression within Vector Biology and across R&D functional teams.
  • Author high-caliber technical reports, early process development summaries, and stage-gate presentations that communicate scientific progress, key process decisions, and development risk assessments to Vector Biology leadership and cross-functional R&D stakeholders.
  • Operate in full adherence to BSL-2 biosafety requirements and Legend Biotech’s research policies; maintain rigorous, contemporaneous electronic laboratory notebook records that meet scientific reproducibility standards and support future transition into GxP-aligned development stages.
  • Champion experimental reproducibility and data integrity through rigorous, organized documentation practices that meet the highest standards of scientific rigor and regulatory traceability.
  • Apply molecular biology expertise to design, engineer, and evaluate LVV constructs encompassing plasmid architecture, packaging system selection, promoter and transgene configuration, and transfer vector optimization to establish high-performing, platform-compatible vectors that meet manufacturability and potency requirements for in-vivo CAR-T applications.

Legend Biotech develops and commercializes cell therapies for serious diseases, including hematologic cancers and solid tumors, with a focus on personalized medicine. Its therapies, like CAR-T treatments, work by collecting a patient’s cells, engineering them to target cancer cells, expanding them, and reinfusing them into the patient. The company differentiates itself by using multiple technology platforms (technology-agnostic) and pursuing a broad pipeline, including exclusive global licenses for CAR-T therapies. Its goal is to bring effective, personalized cell therapies to market, improve outcomes for hard-to-treat cancers, and maintain transparent communication with investors while expanding globally.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Franklin Township, New Jersey

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 CARVYKTI net trade sales grew 62% to $597 million.
  • Ex-U.S. sales surged 222% as launches reached 18 global markets.
  • Near-term in vivo trial readouts could validate a second platform beyond CARVYKTI.

What critics are saying

  • Johnson & Johnson's new Pennsylvania site shifts manufacturing leverage away from Legend.
  • CARVYKTI's gross margin fell to 41% in Q1 2026 from 57%.
  • Legend remains overwhelmingly dependent on CARVYKTI while the rest of pipeline stays pre-commercial.

What makes Legend Biotech unique

  • CARVYKTI is the only approved second-line myeloma CAR-T therapy globally.
  • Legend is advancing in vivo CD19/CD20 CAR-T with lentiviral delivery expertise.
  • Its platform spans autologous, allogeneic, NK, and gamma-delta cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Legend Biotech who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

2%
Yahoo Finance
Mar 10th, 2026
Legend Biotech's CARVYKTI hits $555M Q4 sales, reaches profitability with 10,000-dose capacity

Legend Biotech reported CARVYKTI net trade sales of approximately $555 million in Q4, up 66% year-over-year. Management said CARVYKTI reached profitability in 2025 and expects enterprise-wide profitability in 2026. The therapy is now available in 14 global markets across 294 treatment sites. Legend has installed manufacturing capacity for 10,000 doses, with plans to expand to 20,000 alongside Johnson & Johnson. Manufacturing success rates range from 97% to 99%. Clinical data show median progression-free survival of 50.4 months in triple-class-exposed patients with three prior lines of therapy. Approximately 65% of patients are now treated in the second-to-fourth-line setting, reflecting earlier use in the treatment course. Legend ended 2025 with $949 million in cash and recorded adjusted net income of $2.5 million in Q4.

Yahoo Finance
Mar 10th, 2026
Legend Biotech reports $1.9B CARVYKTI sales for 2025, treats over 10,000 patients

Legend Biotech reported CARVYKTI net trade sales of approximately $555 million in the fourth quarter and $1.9 billion for the full year 2025, achieving franchise profitability. The company has treated over 10,000 patients with its CAR-T therapy and expanded availability to 294 sites across 14 markets worldwide. The company completed expansion of its Raritan facility, creating the largest cell therapy manufacturing site in the United States with capacity to support 10,000 patients annually. Legend Biotech also advanced its pipeline, opening a 31,000-square-foot R&D facility in Philadelphia and dosing the first patient for its in vivo candidates. As of 31 December 2025, Legend Biotech held $949 million in cash and cash equivalents, providing financial runway beyond 2026 when it expects to achieve company-wide operating profit.

Yahoo Finance
Feb 3rd, 2026
Legend Biotech shares drop 46% in 3 months despite $72 fair value estimate

Legend Biotech has raised $120 million in a Series C round led by Ribbit Capital, valuing the pre-revenue AI startup at $1.45 billion. Sequoia and Kleiner Perkins participated, alongside new backer Emerson Collective, bringing total capital raised to $295 million. Co-founded by Robinhood CEO Vlad Tenev, Harmonic develops "Mathematical Superintelligence" that eliminates AI hallucinations by requiring outputs in verifiable Lean4 programming code. Its Aristotle model achieved top performance at the International Mathematical Olympiad in July. Founded in 2023, the company currently offers Aristotle via free API to mathematicians and researchers. It plans future commercialisation targeting safety-critical sectors including aerospace, automotive and finance, where error-free logic is essential.

BioSpace
Jan 29th, 2026
Biotech's Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026

Biotech's next chapter: asset-centric deals and shifting alpha at JPM 2026. January 29, 2026 | After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation. Now that the sound and fury of the J.P. Morgan Healthcare Conference have subsided, investors are taking a step back to evaluate for 2026 the acquisition and capital environment, the buzzy therapeutic spaces and lingering risk factors. Biotech is emerging from a multiyear slump into a new cycle driven by fundamental progress and late-stage assets, said Roderick Wong, managing partner and chief investment officer at New York-based RTW Investments. Although JPM 2026 felt light on headline megadeals, record-setting M&A rumors before the conference around Revolution Medicines (reported to be in talks with Merck and AbbVie) and Abivax (with Eli Lilly speculation takeover) underscored strong demand for high quality, late-stage development assets, Wong said. Actual announced deals (e.g., Eli Lilly - Ventyx Biosciences, GlaxoSmithKline - RAPT Therapeutics, Boston Scientific - Penumbra) reinforced that asset-centric transactions are with clear blockbuster or strategic potential are the most interesting, Wong said. From RTW's vantage point and reinforced by several VC conversations on the sidelines of JPM26, asset-focused companies remain more attractive than pure platform or technology plays in the current environment. Hot therapeutic investment spaces. Key disease areas of focus include oncology (pancreatic, breast, bladder), where several programs could reset standards of care and address major unmet needs, noted Stephanie Sirota, partner and chief business officer at RTW. Obesity is another major theme, with anticipation around the first true small-molecule pill from Eli Lilly and a next wave of novel mechanisms, Wong said. One of RTW's portfolio companies, Corxel, announced on January 23 a $287 million Series D fundraising. Neuroscience/CNS has seen a sharp sentiment shift, with investors leaning back into space after years of limited innovation, Wong and Sirota agreed. Their comments echo those heard on the sidelines of JPM26; that advances in biomarkers, brain mapping and AI, as well as a rapidly aging population, support investment in the space. Psychedelics exemplify a potential paradigm shift in depression treatment modality, Wong said, with Compass Pathways' Phase III data and a possible near-term launch supporting nondaily, episodic treatment models. The cultural and medical shift in psychedelic therapeutic is one of the topics explored in the RTW's latest book "Innovation is the Best Medicine." FDA remains a risk factor. The degree of policy risk for the biopharma sector has declined significantly since the start of the Trump administration last year, Wong said. At the time, major uncertainties surrounded tariffs, manufacturing reshoring and Most Favored Nations drug pricing negotiations. What has evolved are reasonable resolutions that have been neutral to modestly negative rather than worstcase scenarios, he added. There have been many discussions around the chaotic year at the FDA in 2025, including a revolving door of senior staff members. The main remaining structural risk, Wong said, is FDA behavior in "edge cases," particularly in rare diseases and emerging modalities like gene and cell therapies, using nontraditional trial designs, surrogate endpoints or single arm studies. Last year's players in this space saw negative feedback or rejection, discussed in greater depth in the RTW book. RTW is responding by being more conservative around such edge case programs, which it expects will depress capital flows into some rare disease and early modality assets. Alpha stacking model. The firm frames its investment process as "alpha stacking:" starting with rigorous fundamental equity analysis (science underwriting plus commercial forecasting) and layering on multiple, evolving sources of information and assessment, Sirota said. This includes collecting information on policy, considering transactional and operational models, as well as what is compelling from a buyer perspective. The firm has built deep therapeutic specialization plus functional expertise (e.g., IP, geography such as China) to move beyond headline-driven views of risk and opportunity. RTW has also invested internally in data science, automation and AI to enhance its research process, they agreed. Ultimately, investment is always evolving, Wong said. He noted that a scientific background at one was the advantage - an alpha - one had when investing, but that's become understood. Rather, alpha stacking is now about intentionally trying to understand where the advantages lie and staying on top of these evolving factors. In this episode of Denatured, Jennifer C. Smith-Parker speaks with RTW's Rod Wong and Stephanie Sirota how shifting JPM deal timing masks record M&A potential; why oncology, obesity, psychedelics, and neuroscience are attracting fresh capital; and how "alpha stacking" shapes their investment edge in an age of chronic uncertainty. January 29, 2026

Stock Titan
Aug 18th, 2025
[6-K] Legend Biotech Corporation American Current Report (Foreign Issuer)

On August 18, 2025, Legend Biotech Corporation announced the appointment of Carlos Santos as the Company's Chief Financial Officer ("CFO").